Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 2.36 million shares on December 3, 2025, marking a total net increase of 10.81 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings on 12 occasions, resulting in a cumulative net increase of 8.71 million shares [1] - As of now, southbound funds hold 904 million shares of MicroPort Medical, accounting for 47.27% of the company's total issued ordinary shares [1] Summary by Category Shareholding Changes - On December 3, 2025, total shares held reached 904 million, with a change of 2.36 million shares, representing a 0.26% increase [2] - On December 2, 2025, total shares held were 902 million, with a change of 2.54 million shares, representing a 0.28% increase [2] - On December 1, 2025, total shares held were 276.68 million, with a change of 361,100 shares, representing a 0.04% increase [2] - On November 28, 2025, total shares held were 266.8 million, with a change of 1.55 million shares, representing a 0.17% increase [2] - On November 27, 2025, total shares held were 898 million, with a change of 4 million shares, representing a 0.45% increase [2] Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [2] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, large artery and peripheral vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), indicating strong investor interest and confidence in the company's performance [1]. Group 1: Southbound Fund Holdings - On December 1, southbound funds increased their holdings by 361,100 shares [2]. - Over the past five trading days, there were four days of net increases, totaling 6,722,700 shares [1]. - In the last 20 trading days, there were 11 days of net increases, amounting to 9,681,000 shares [1]. - As of now, southbound funds hold 899 million shares of MicroPort, representing 47.01% of the company's total issued ordinary shares [1]. Group 2: Trading Data Summary - On December 1, total shares held were 266.8 million, with a change of 361,100 shares, reflecting a 0.04% increase [2]. - On November 28, total shares held were 266.8 million, with a change of 1,550,400 shares, reflecting a 0.17% increase [2]. - On November 27, total shares held were 898 million, with a change of 4,000,100 shares, reflecting a 0.45% increase [2]. - On November 26, total shares held were 894 million, with a change of 1,115,800 shares, reflecting a 0.13% increase [2]. - On November 25, total shares held were 892 million, with a change of -304,700 shares, reflecting a -0.03% decrease [2]. Group 3: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [2]. - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [2].

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

Group 1 - The 2025 Analyst Conference highlighted the optimism surrounding the Chinese capital market, with expectations of a significant influx of global capital into A-shares [1] - The conference gathered over 300 influential figures, including scholars, fund managers, and company executives, to discuss future opportunities in the capital market [1] Group 2 - The strategy for the high-value consumables sector indicates a positive outlook due to the completion of major category procurement and optimized payment policies, with revenue growth and profit recovery expected by 2025 [2] - The medical equipment sector is anticipated to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is expected to regain growth, supported by revenue and profit recovery in 2025, with potential growth from international expansion [2] Group 3 - Investment recommendations include high-value consumables companies like Microelectrophysiology, Aikang Medical, and others, which are expected to benefit from the clearing of procurement risks and the launch of new products [3] - Medical equipment and home medical companies such as Mindray Medical and others are recommended for steady revenue growth due to the recovery of bidding processes and international expansion [3]

Group 1 - Hong Kong's Hang Seng Index fell by 0.24%, down 61 points, closing at 25,884 points, while the Hang Seng Tech Index rose by 0.11% [1] - Bubble Mart (09992) surged over 4%, leading the blue-chip stocks in the Hang Seng Index, supported by government encouragement for trendy toy consumption during the traditional sales peak [1] - GAC Group (02238) increased by over 12% as Aion UT Super commenced full delivery and solid-state battery production lines were established [1] - Zijin Mining International (02259) rose over 2% as production from its mines increased, entering a growth phase in the coming years [1] Group 2 - Dongyue Group (00189) rose by 4.62%, with institutions indicating that strong demand for lithium batteries is expected to persist, and PVDF prices are likely to increase [2] - MicroPort Medical (00853) increased by 5%, with Morgan Stanley purchasing over HKD 900 million in shares, while Bank of America remains optimistic about its surgical robotics business [3] - Bole Technology (02592) surged by 12.8% after its core product CBT-009 received patents in Japan and Europe [4] - Cambridge Technology (06166) rose over 4%, with expectations of significant shipments of 1.6T optical modules in Q1 2026 [5] - Hezhima Intelligent (02533) and Joyson Electronics (00699) both increased by over 4% as they collaborated to develop multi-chip platform robotic domain control products [5] - New stock Haiwei Co., Ltd. (09609) debuted with a 15% drop, being the second-largest capacitor film manufacturer in China [5]

Group 1 - Hong Kong's Hang Seng Index fell by 0.24%, down 61 points, closing at 25,884 points, while the Hang Seng Tech Index rose by 0.11% [1] - Pop Mart (09992) surged over 4%, leading the blue-chip stocks in the Hang Seng Index, supported by government encouragement for trendy toy consumption as the traditional sales season approaches [2] - GAC Group (02238) increased by over 12% following the full delivery of its Aion UT super model and the establishment of a solid-state battery production line [3] Group 2 - Zijin Mining International (02259) rose over 2% as its mining output increased, entering a growth phase in the coming years [4] - Dongyue Group (00189) saw a 4.62% increase, with institutions indicating strong demand for lithium batteries and potential price hikes for PVDF [5] - MicroPort Medical (00853) gained 5% as JPMorgan increased its stake by over HKD 900 million, with Bank of America expressing optimism about its surgical robot business [6] Group 3 - Bole Technology (02592) surged by 12.8% after its core product CBT-009 received patents in Japan and Europe [7] - Cambridge Technology (06166) rose over 4%, with expectations of significant shipments of its 1.6T optical modules in Q1 2026 [8] - Hezhima Intelligent (02533) and Joyson Electronics (00699) both increased by over 4% as they collaborate on a multi-chip platform for robotic domain control products [9] Group 4 - New stock Haiwei Co., Ltd. (09609) debuted with a 15% drop, being the second-largest capacitor film manufacturer in China [10] Group 5 - Food and Beverage ETF (Product Code: 515170) experienced a decline of 1.37% over the past five days, with a PE ratio of 20.73 times and a net redemption of HKD 1.719 million [12] - Gaming ETF (Product Code: 159869) rose by 4.31% over the past five days, with a PE ratio of 36.47 times and a net redemption of HKD 74.789 million [12] - Sci-Tech 50 ETF (Product Code: 588000) fell by 1.21% over the past five days, with a high PE ratio of 147.81 times and a net redemption of HKD 1.54 billion [12]

Group 1: Market Overview - The Hang Seng Index fell by 0.24%, down 61 points, closing at 25,884 points, while the Hang Seng Tech Index rose by 0.11% [1] - The Hong Kong stock market saw a morning turnover of HKD 75.5 billion [1] Group 2: Notable Stock Movements - Pop Mart (09992) surged over 4%, leading the blue-chip stocks in the Hang Seng Index, supported by government encouragement for trendy toy consumption as the traditional sales peak season approaches [1] - GAC Group (601238) (02238) increased by over 12% following the full delivery of the Aion UT super and the establishment of a solid-state battery production line [1] - Zijin Mining International (02259) rose over 2% as its mining output increased, entering a growth phase in the coming years [2] - Dongyue Group (00189) saw a 4.62% increase, with institutions expecting strong demand for lithium batteries to be sustained and potential price increases for PVDF [3] - MicroPort Medical (00853) gained 5%, with JPMorgan increasing its stake by over HKD 900 million, and Bank of America expressing optimism about its surgical robot business [4] - Bole Technology (02592) surged 12.8% after its core product CBT-009 received patents in Japan and Europe [5] - Cambridge Technology (603083) (06166) rose over 4%, anticipating significant shipments of its 1.6T optical module in Q1 2026 [5] - Black Sesame Technologies (000716) (02533) and Joyson Electronics (600699) (00699) both increased by over 4%, collaborating to develop multi-chip platform robotic domain control products [5] - New stock Haiwei Co., Ltd. (09609) debuted with a 15% drop, being the second-largest capacitor film manufacturer in China [6]

Group 1 - MicroPort Medical (0853.HK) saw a rise of over 5%, reaching HKD 11.36, with a total market capitalization of HKD 21.655 billion [1] - According to the Hong Kong Stock Exchange, JPMorgan increased its stake in MicroPort Medical by acquiring 89.0604 million shares at an average price of HKD 10.4413 per share on November 24, totaling approximately HKD 930 million [1] - Bank of America Securities reaffirmed a "Buy" rating for MicroPort Medical, citing attractive risk-reward dynamics and a diversified high-value consumables product portfolio, with surgical robotics expected to be a key growth driver [1] Group 2 - The company is projected to achieve profitability by the first half of 2026, with revenue forecasts for 2026 to 2034 adjusted upward by 0.1% to 1.5% [1] - The target price for MicroPort Medical has been slightly increased from HKD 16.8 to HKD 17 [1]

Group 1 - MicroPort Medical (00853.HK) saw a morning increase of over 4%, currently up 4.53% at HKD 11.3 [1] - The trading volume reached HKD 80.5031 million [1]